Michelle MBA - Sirona Biochem VP Operations
| SRBCF Stock | USD 0.05 0.01 12.50% |
Insider
Michelle MBA is VP Operations of Sirona Biochem Corp
| Phone | 604 641 4466 |
| Web | https://www.sironabiochem.com |
Sirona Biochem Management Efficiency
The company has return on total asset (ROA) of (1.3502) % which means that it has lost $1.3502 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (35.557) %, meaning that it generated substantial loss on money invested by shareholders. Sirona Biochem's management efficiency ratios could be used to measure how well Sirona Biochem manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Yuemei Yan | Ascletis Pharma | 53 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Mark Meier | Fennec Pharmaceuticals | N/A | |
| Ellen MBA | Werewolf Therapeutics | 48 | |
| Edith MD | Bolt Biotherapeutics | 67 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Jason Davis | Virax Biolabs Group | 52 | |
| Francis Conway | Larimar Therapeutics | N/A | |
| Nancy Ruiz | Larimar Therapeutics | N/A | |
| Reid Leonard | Werewolf Therapeutics | 65 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| James JD | Eliem Therapeutics | 58 | |
| Kenneth MD | Cue Biopharma | 64 | |
| Alexander MS | Fennec Pharmaceuticals | N/A | |
| Michael Wolfe | Kezar Life Sciences | N/A | |
| Kishor Bhatia | Lantern Pharma | 69 | |
| Elizabeth Nguyen | Surrozen | N/A | |
| Oz CPA | Scisparc | 38 | |
| John CPA | Unicycive Therapeutics | 62 | |
| Jinzi Wu | Ascletis Pharma | 60 | |
| Noreen MD | Kezar Life Sciences | 59 | |
Management Performance
| Return On Equity | -35.56 | |||
| Return On Asset | -1.35 |
Sirona Biochem Corp Leadership Team
Elected by the shareholders, the Sirona Biochem's board of directors comprises two types of representatives: Sirona Biochem inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sirona. The board's role is to monitor Sirona Biochem's management team and ensure that shareholders' interests are well served. Sirona Biochem's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sirona Biochem's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CGA, CFO Director | ||
| Graldine DeliencourtGodefroy, Chief Director | ||
| Michelle MBA, VP Operations | ||
| Brett Premack, Scientific Consultant |
Sirona Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sirona Biochem a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -35.56 | |||
| Return On Asset | -1.35 | |||
| Operating Margin | (4.92) % | |||
| Current Valuation | 24.5 M | |||
| Shares Outstanding | 251.73 M | |||
| Shares Owned By Insiders | 10.43 % | |||
| Price To Earning | (7.33) X | |||
| Price To Book | 36.93 X | |||
| Price To Sales | 36.46 X | |||
| Revenue | 268.02 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Sirona Pink Sheet
Sirona Biochem financial ratios help investors to determine whether Sirona Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sirona with respect to the benefits of owning Sirona Biochem security.